-
Mashup Score: 34
Skeletal metastases portend a poor prognosis for patients with neuroendocrine tumors (NETs). Literature on peptide receptor radionuclide therapy (PRRT) specific to patients with skeletal metastases from NETs is scarce. This study assessed real-world clinical outcomes of 177Lu-DOTATATE PRRT in this patient subgroup. Methods: Data from consecutive patients with well-differentiated NETs and skeletal metastases treated with 177Lu-DOTATATE at our center from January 2014 until August 2024 were retrospectively reviewed. Safety, efficacy, progression-free survival (PFS), and overall survival (OS) outcomes were analyzed. Results: In total, 288 PRRT cycles were administered to 74 patients. The median number of PRRT cycles was 4 (interquartile range, 2–6), and the median cumulative activity was 21.3 GBq (interquartile range, 11.1–33.3 GBq). The best objective response rates, evaluated using modified M.D. Anderson criteria (bone metastases) and RECIST 1.1 (overall response), were 31% and 23%, res
Source: jnm.snmjournals.orgCategories: General Medicine NewsTweet
-
Mashup Score: 23[18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study - 17 day(s) ago
[18F]FDG PET/CT avidity predicts higher-grade disease and worse prognosis in patients with metastatic neuroendocrine neoplasm. However, there is less evidence regarding the role of [18F]FDG-avid tumor volume in predicting prognosis. We planned to determine whether metabolic tumor volume (MTV) on [18F]FDG PET/CT predicts prognosis in patients with advanced gastroenteropancreatic neuroendocrine neoplasm (GEPNEN). Methods: A multicenter retrospective study was performed on patients with advanced GEPNEN who underwent [18F]FDG PET/CT in a previously established cohort. Images were acquired across 3 centers using harmonized protocols and were contoured and verified at a flat SUV threshold of 4 using a semiautomated software workflow. The primary endpoint was overall survival. Patients were dichotomized into high- and low-MTV groups by the median value, with the overall survival of the 2 resulting cohorts compared by log-rank tests and multivariate analyses. Results: In total, 231 patients we
Source: jnm.snmjournals.orgCategories: General Medicine NewsTweet-
More on FDG PET in well diff NETs: Not surprisingly, the FDG metabolic tumor volume is associated with shorter survival and time to treatment failure. And a higher grade, of course... The question is: Does this add value and if so, will it be covered...? https://t.co/r8DehpVhrs
-
-
Mashup Score: 10
Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce mortality. Neuroblastoma expresses several molecular targets for radionuclide imaging and therapy, of which the most widely exploited is the norepinephrine transporter. [123I]metaiodobenzylguanidine (MIBG) imaging and [131I]MIBG treatment, which target this physiologic pathway, have been in clinical practice for 40 y. Although therapy outcomes have been favorable, [131I]MIBG use has not yet been optimized. Somatostatin receptors and the disialoganglioside are alternative targets, but their use remains experimental. The charity Children’s Cancer Research Fund organized a workshop bringing together a broad range of scientists including radiochemists, radiobiologists, radiation physicists, clinical researchers including pediatric oncologists and nuclear medicine physicians, and patient advoca
Source: jnm.snmjournals.orgCategories: General Medicine NewsTweet-
RT @JournalofNucMed: Theranostics for neuroblastoma: Making molecular radiotherapy work better. https://t.co/UNz7ptpdkW #NuclearMedicine #…
-
-
Mashup Score: 2Funding Reductions Threaten the Future of Medical Innovation - 26 day(s) ago
As medical researchers and clinicians, we are concerned about the proposed reductions in funding for the U.S. National Institutes of Health (NIH), Department of Energy (DoE), and Department of Defense (DoD) medical research programs. These reductions threaten progress in treatments for cancer as
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @CzerninJohannes: Funding Reductions Threaten the Future of Medical Innovation https://t.co/vtdwom5wpn
-
-
Mashup Score: 15
Metabolic tumor volume (MTV) is a promising biomarker of pretreatment risk in diffuse large B-cell lymphoma (DLBCL). Different segmentation methods can be used that predict prognosis equally well but give different optimal cutoffs for risk stratification. Segmentation can be cumbersome; a fast, easy, and robust method is needed. Our aims were to evaluate the best automated MTV workflow in DLBCL; determine whether uptake time, compliance or noncompliance with standardized recommendations for 18F-FDG scanning, and subsequent disease progression influence the success of segmentation; and assess differences in MTVs and discriminatory power of segmentation methods. Methods: One hundred forty baseline 18F-FDG PET/CT scans were selected from U.K. and Dutch studies on DLBCL to provide a balance between scans at 60 and 90 min of uptake, parameters compliant and noncompliant with standardized recommendations for scanning, and patients with and without progression. An automated tool was applied f
Source: jnm.snmjournals.orgCategories: General Medicine NewsTweet-
#Hematology Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell #Lymphoma #DLBCL: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium #lymsm https://t.co/5OZi7kfyYV
-
-
Mashup Score: 2Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy - 4 month(s) ago
Patients with metastatic neuroendocrine tumors (NETs) can present with hundreds of lesions, and each lesion might have a unique response pattern to peptide receptor radiopharmaceutical therapy (PRRT). This response heterogeneity has been observed but is poorly understood. In this work, we perform a quantitative analysis of longitudinal PET/CT scans to comprehensively characterize the NET response to PRRT. Methods: NET patients treated with [177Lu]Lu-DOTATATE PRRT imaged at baseline, during, and after PRRT with [68Ga]Ga-DOTATATE PET/CT were enrolled in this retrospective single-institutional study. A deep-learning model was used to identify and contour regions of nonphysiological elevated tracer uptake (lesion-regions of interest [ROIs]). An automated analysis was performed to identify, contour, and quantify the individual lesion-ROI uptake, match ROI between time points, and categorize each lesion-ROI as disappearing, decreasing (ΔSUVtotal < −30%), stable (−30% ≤ ΔSUVtotal ≤ 30%), incr
Source: jnm.snmjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Response assessment following PRRT in patients with metastatic NETs. Not as simple as one might have thought... Response heterogeneity in all patients in this small study. https://t.co/bha3xNs98Y
-
-
Mashup Score: 111Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study - 5 month(s) ago
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging. The aim of this retrospective multicenter study was to compare the CI-based disease volume criteria to PSMA PET–based volume definitions in a CHAARTED-like cohort. Methods: mHSPC patients from 5 international sites who underwent PSMA PET/CT or PSMA PET/MRI and BS within a time interval of 100 d and without initiation of a new therapy between the 2 scans were retrospectively included in the analysis. CHAARTED HVD and LVD criteria were applied to BS, CT, MRI, and PSMA PET. HVD was defined by the presence of visceral metastases or at least 4 bone metastases
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet-
Low- and High-Volume Disease in mHSPC: from CHAARTED to #PSMA PET #stagemigration https://t.co/POmcfhRIzh @UnterrainerLena @JournalofNucMed @thomashopemd @UCLAHealth @SathegkeM @AmarUKishan @CzerninJohannes @ProfKHerrmann @Wes_Armstrong_ https://t.co/80yXxU3i0l
-
-
Mashup Score: 47
177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials. Methods: In this investigator-initiated, parallel-group, open-label, phase 2 trial, patients with grade 1/2 GEP-NETs, having progressive somatostatin receptor–positive, locally advanced, or metastatic disease on 68Ga-DOTANOC PET/CT, were randomly assigned in a 1:1 ratio to 177Lu-DOTATATE plus capecitabine (experimental arm) or 177Lu-DOTATATE only (control arm). 177Lu-DOTATATE was administered at approximately 7.4 GBq/cycle intravenously, for up to 4 cycles, at 8 wk intervals, whereas capecitabine was given at 1,250 mg/m2/d orally from day 0 to day 14 of each cycle of 177Lu-DOTATATE. The primary endpoint was the
Source: jnm.snmjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Does radiosensitizing capecitabine improve the efficacy of PRRT in progressive GEPNETs...? This small phase II RCT does not suggest so and I remain thoroughly unconvinced that adding chemo to PRRT does anything beneficial. Big kudos to this team! https://t.co/w6VCk0lS9X
-
-
Mashup Score: 94Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study - 5 month(s) ago
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging. The aim of this retrospective multicenter study was to compare the CI-based disease volume criteria to PSMA PET–based volume definitions in a CHAARTED-like cohort. Methods: mHSPC patients from 5 international sites who underwent PSMA PET/CT or PSMA PET/MRI and BS within a time interval of 100 d and without initiation of a new therapy between the 2 scans were retrospectively included in the analysis. CHAARTED HVD and LVD criteria were applied to BS, CT, MRI, and PSMA PET. HVD was defined by the presence of visceral metastases or at least 4 bone metastases
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet-
Low- and High-Volume Disease in mHSPC: from CHAARTED to #PSMA PET #stagemigration https://t.co/POmcfhRIzh @UnterrainerLena @JournalofNucMed @thomashopemd @UCLAHealth @SathegkeM @AmarUKishan @CzerninJohannes @ProfKHerrmann @Wes_Armstrong_ https://t.co/80yXxU3i0l
-
-
Mashup Score: 75Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study - 5 month(s) ago
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific membrane antigen (PSMA) PET imaging. The aim of this retrospective multicenter study was to compare the CI-based disease volume criteria to PSMA PET–based volume definitions in a CHAARTED-like cohort. Methods: mHSPC patients from 5 international sites who underwent PSMA PET/CT or PSMA PET/MRI and BS within a time interval of 100 d and without initiation of a new therapy between the 2 scans were retrospectively included in the analysis. CHAARTED HVD and LVD criteria were applied to BS, CT, MRI, and PSMA PET. HVD was defined by the presence of visceral metastases or at least 4 bone metastases
Source: jnm.snmjournals.orgCategories: General Medicine News, Partners & KOLsTweet-
Low- and High-Volume Disease in mHSPC: from CHAARTED to #PSMA PET #stagemigration https://t.co/POmcfhRIzh @UnterrainerLena @JournalofNucMed @thomashopemd @UCLAHealth @SathegkeM @AmarUKishan @CzerninJohannes @ProfKHerrmann @Wes_Armstrong_ https://t.co/80yXxU3i0l
-
Lu-177 DOTATATE PRRT in patients with NETs and extensive bone metastases. Is it effective and is it safe? It looks like the answer is yes to both and indeed, we use it frequently under such circumstances. Skeletal related events were 20%... https://t.co/Wj0IwKe3yS